Mechanisms and emerging treatments of the metabolic complications of chronic pancreatitis

Pancreas

Volumn 35, Issue 1, 2007, Pages 1-15

  Andersen, Dana K ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Chronic pancreatitis; Insulin; Insulin receptor (IR); Pancreatic polypeptide (PP); Pancreatogenic diabetes; Plasma membrane

Indexed keywords

BIOLOGICAL MARKER; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE TRANSPORTER 2; INSULIN; INSULIN RECEPTOR; PANCREAS POLYPEPTIDE;

ALCOHOLISM; AUTOIMMUNE DISEASE; BLOOD GLUCOSE MONITORING; CELL MEMBRANE; CHRONIC PANCREATITIS; CLINICAL FEATURE; CONTINUOUS INFUSION; COVALENT BOND; CYSTIC FIBROSIS; DIABETES MELLITUS; DIABETIC OBESITY; ENDOCYTOSIS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN BINDING; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN TREATMENT; LABORATORY TEST; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS CALCIFICATION; PANCREAS RESECTION; PANCREATIC POLYPEPTIDE DEFICIENCY; PANCREATICODUODENECTOMY; PHASIC INSULIN DEPENDENT DIABETES MELLITUS; PHOSPHORYLATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; TREATMENT OUTCOME;

ANIMALS; DIABETES MELLITUS; HUMANS; ISLETS OF LANGERHANS; PANCREATITIS, CHRONIC;

EID: 34250741968     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/mpa.0b013e31805d01b0     Document Type: Review

References (82)

1. DiMagno EP, Go VL, Summerskill WH. Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency. N Engl J Med. 1973;288(16):813-815.
2. Dutta SK, Russell RM, Iber FL. Influence of exocrine pancreatic insufficiency on the intraluminal pH of the proximal small intestine. Dig Dis Sci. 1979;24(7):529-534.
3. Layer P, Go VL, DiMagno EP. Fate of pancreatic enzymes during small intestinal aboral transit in humans. Am J Physiol. 1986;251(4 Pt 1):G475-G480.
4. Layer P, Holtmann G. Pancreatic enzymes in chronic pancreatitis. Int J Pancreatol. 1994;15(1):1-11.
5. Ganda O. Secondary forms of diabetes. In: Kahn CR, Weir GC, eds. Joslin's Diabetes Mellitus. New York: Lea & Febiger; 1994.
6. Tiengo A, Alberti KGMM, Del Prato S, et al. Diabetes secondary to pancreatopathy: new pancreatopathy. In: Tiengo A, Alberti KGMM, Del Prato S, et al, eds. Diabetes Secondary to Pancreatopathy: Proceedings of the Post EASD International Symposium on Diabetes Secondary to Pancreatopathy, Padova, Italy, 21-22 September 1987. Amsterdam: Excerpta Medica; 1988;35-50.
7. Abu-Bakare A, Taylor R, Gill GV, et al. Tropical or malnutrition-related diabetes: a real syndrome? Lancet. 1986;1(8490):1135-1138.
8. Mohan V, Pitchumoni C. Tropical chronic pancreatitis. In: Beger HG, ed. The Pancreas. London: Blackwell-Science; 1998:688-697.
9. Frey CF, Child CG, Fry W. Pancreatectomy for chronic pancreatitis. Ann Surg. 1976;184(4):403-413.
10. Slezak LA, Andersen DK. Pancreatic resection: effects on glucose metabolism. World J Surg. 2001;25(4):452-460.
11. Alberti K. Diabetes Secondary to Pancreatopathy: an example of brittle diabetes. In: Tiengo A, ed. Diabetes secondary to pancreatopathy: proceedings of the Post EASD International Symposium on Diabetes Secondary to Pancreatopathy, Padova, Italy, 21-22 September 1987, International congress series. Amsterdam: Excerpta Medica; 1988:211-214.
12. Gall FP, Muhe E, Gebhardt C. Results of partial and total pancreaticoduodenectomy in 117 patients with chronic pancreatitis. World J Surg. 1981;5(2):269-275.
13. Couet C, Genton P, Pointel JP, et al. The prevalence of retinopathy is similar in diabetes mellitus secondary to chronic pancreatitis with or without pancreatectomy and in idiopathic diabetes mellitus. Diabetes Care. 1985;8(4):323-328.
14. Bank S. Chronic pancreatitis: clinical features and medical management. Am J Gastroenterol. 1986;81(3):153-167.
15. Nyboe Andersen B, Krarup T, Thorsgaard Pedersen NT, et al. B cell function in patients with chronic pancreatitis and its relation to exocrine pancreatic function. Diabetologia. 1982;23(2):86-89.
16. Malka D, Hammel P, Sauvanet A, et al. Risk factors for diabetes mellitus in chronic pancreatitis. Gastroenterology. 2000;119(5):1324-1332.
17. Kloppel G, Bommer G, Commandeur G, et al. The endocrine pancreas in chronic pancreatitis. Immunocytochemical and ultrastructural studies. Virchows Arch A Pathol Anat Histol. 1978;377(2):157-174.
18. Davalli AM, Pontiroli AE, Bertuzzi F, et al. In vitro function of human islets isolated from the pancreas of a cadaveric donor with diabetes mellitus secondary to chronic pancreatitis. Pancreas. 1994;9(1):134-136.
19. Hedetoft C, Sheikh SP, Larsen S, et al. Effect of glucagon-like peptide 1(7-36)amide in insulin-treated patients with diabetes mellitus secondary to chronic pancreatitis. Pancreas. 2000;20(1):25-31.
20. Yeo CJ, Bastidas JA, Schmieg RE Jr, et al. Pancreatic structure and glucose tolerance in a longitudinal study of experimental pancreatitis-induced diabetes. Ann Surg. 1989;210(2):150-158.
21. Andres R, Swerdloff R, Pozefsky T, et al. Manual feedback technique for control of glucose concentration. In: Skeggs L Jr, ed. Automation in Analytic Chemistry. New York: Medaid, Inc; 1966:486-501.
22. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci. 1959;82:420-430.
23. Sun YS, Brunicardi FC, Druck P, et al. Reversal of abnormal glucose metabolism in chronic pancreatitis by administration of pancreatic polypeptide. Am J Surg. 1986;151(1):130-140.
24. Donowitz M, Hendler R, Spiro HM, et al. Glucagon secretion in acute and chronic pancreatitis. Ann Intern Med. 1975;83(6):778-781.
25. Valenzuela JE, Taylor IL, Walsh JH. Pancreatic polypeptide response in patients with chronic pancreatitis. Dig Dis Sci. 1979;24(11):862-864.
26. Glaser B, Vinik AI, Sive AA, et al. Plasma human pancreatic polypeptide responses to administered secretin: effects of surgical vagotomy, cholinergic blockade, and chronic pancreatitis. J Clin Endocrinol Metab. 1980;50(6):1094-1099.
27. Bastidas JA, Couse NF, Yeo CJ, et al. The effect of pancreatic polypeptide infusion on glucose tolerance and insulin response in longitudinally studied pancreatitis-induced diabetes. Surgery. 1990;107(6):661-668.
28. Seymour NE, Turk JB, Laster MK, et al. In vitro hepatic insulin resistance in chronic pancreatitis in the rat. J Surg Res. 1989;46(5):450-456.
29. Mundlos S, Adler G, Schaar M, et al. Exocrine pancreatic function in oleic acid-induced pancreatic insufficiency in rats. Pancreas. 1986;1(1):29-36.
30. Hanks JB, Meyers WC, Wellman CL, et al. The effect of cell-free and erythrocyte-containing perfusion in rat livers. J Surg Res. 1980;29(2):149-160.
31. Andersen DK, Ruiz CL, Burant CF. Insulin regulation of hepatic glucose transporter protein is impaired in chronic pancreatitis. Ann Surg. 1994;219:679-686. [discussion 686-687].
32. Goldstein JA, Kirwin JD, Seymour NE, et al. Reversal of in vitro hepatic insulin resistance in chronic pancreatitis by pancreatic polypeptide in the rat. Surgery. 1989;106(6):1128-1132. [discussion 1132-1133].
33. Whitcomb DC, Taylor IL, Vigna SR. Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain. Am J Physiol. 1990;259:G687-G691.
34. Seymour NE, Spector SA, Andersen DK, et al. Overexpression of hepatic pancreatic polypeptide receptors in chronic pancreatitis. J Surg Res. 1998;76(1):47-52.
35. Seymour NE, Brunicardi FC, Chaiken RL, et al. Reversal of abnormal glucose production after pancreatic resection by pancreatic polypeptide administration in man. Surgery. 1988;104(2):119-129.
36. Brunicardi FC, Chaiken RL, Ryan AS, et al. Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. J Clin Endocrinol Metab. 1996;81(10):3566-3572.
37. Seymour NE, Andersen DK. Pancreatic polypeptide and glucose metabolism. In: Greeley GH, ed. Gastrointestinal Endocrinology. Totowa, NJ: Humana Press; 1999:321-334.
38. Kono T, Wang XP, Fisher WE. Pancreatic polypeptide (PP). In: Martini L, ed. Encyclopedia of Endocrine Diseases. San Diego, CA: Elsevier; 2004:488-496.
39. Orci L. Macro- and micro-domains in the endocrine pancreas. Diabetes. 1982;31(6 Pt 1):538-565.
40. Schwartz TW, Rehfeld JF, Stadil F, et al. Pancreatic-polypeptide response to food in duodenal-ulcer patients before and after vagotomy. Lancet. 1976;1(7969):1102-1105.
41. Taylor IL. Pancreatic Polypeptide Family: Pancreatic Polypeptide, Neuropeptide Y, and Peptide YY. 2nd ed. Bethesda, MD: American Physical Society; 1989.
42. Putnam WS, Liddle RA, Williams JA. Inhibitory regulation of rat exocrine pancreas by peptide YY and pancreatic polypeptide. Am J Physiol. 1989;256(4 Pt 1):G698-G703.
43. Hazelwood RL. The pancreatic polypeptide (PP-fold) family: gastrointestinal, vascular, and feeding behavioral implications. Proc Soc Exp Biol Med. 1993;202(1):44-63.
44. Schober DA, Van Abbema AM, Smiley DL, et al. The neuropeptide Y Y1 antagonist, 1229U91, a potent agonist for the human pancreatic polypeptide-preferring (NPY Y4) receptor. Peptides. 1998;19:537-542.
45. Pheng LH, Perron A, Quirion R, et al. Neuropeptide Y-induced contraction is mediated by neuropeptide Y Y2 and Y4 receptors in the rat colon. Eur J Pharmacol. 1999;374(1):85-91.
46. Berglund MM, Hipskind PA, Gehlert DR. Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp Biol Med (Maywood). 2003;228(3):217-244.
47. Gettys TW, Garcia R, Savage K, et al. Insulin-sparing effects of pancreatic polypeptide in congenitally obese rodents. Pancreas. 1991;6(1):46-53.
48. Seymour NE, Volpert AR, Lee EL, et al. Alterations in hepatocyte insulin binding in chronic pancreatitis: effects of pancreatic polypeptide. Am J Surg. 1995;169(1):105-109. [discussion 110].
49. Seymour NE, Volpert AR, Andersen DK. Regulation of hepatic insulin receptors by pancreatic polypeptide in fasting and feeding. J Surg Res. 1996;65:1-4.
50. Spector SA, Frattini JC, Zdankiewicz PD, et al. Insulin receptor gene expression in chronic pancreatitis: the effect of pancreatic polypeptide. Surg Forum. 1997;48:168-171.
51. Bruning JC, Michael MD, Winnay JN, et al. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell. 1998;2(5):559-569.
52. Michael MD, Kulkarni RN, Postic C, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell. 2000;6(1):87-97.
53. Fisher SJ, Kahn CR. Insulin signaling is required for insulin's direct and indirect action on hepatic glucose production. J Clin Invest. 2003;111(4):463-468.
54. Adrian TE, Greenberg GR, Bloom SR. Actions of pancreatic polypeptide in man. In: Bloom SR, Polak M, eds. Gut hormones. Edinburgh: Churchill-Livingstone; 1981:206-212.
55. Gorden P, Carpentier JL, Freychet P, et al. Intracellular translocation of iodine-125-labeled insulin: direct demonstration in isolated hepatocytes. Science. 1978;200(4343):782-785.
56. Carpentier JL, Gorden P, Freychet P, et al. Lysosomal association of internalized 125I-insulin in isolated rat hepatocytes. Direct demonstration by quantitative electron microscopic autoradiography. J Clin Invest. 1979;63(6):1249-1261.
57. Desbuquois B, Lopez S, Burlet H. Ligand-induced translocation of insulin receptors in intact rat liver. J Biol Chem. 1982;257(18):10852-10860.
58. Slezak LA, Nathan JD, Zdankiewicz PD, et al. Impaired hepatocyte insulin receptor internalization in chronic pancreatitis. Surg Forum. 1998;49:152-153.
59. Maker AV, Slezak LA, Aspelund G, et al. Impaired phosphorylation of hepatic insulin receptor and glucose transporter proteins in chronic pancreatitis. Surg Forum. 1999;50:14-16.
60. Eisenberg ML, Maker AV, Slezak LA, et al. Insulin receptor (IR) and glucose transporter 2 (GLUT2) proteins form a complex on the rat hepatocyte membrane. Cell Physiol Biochem. 2005;15:51-58.
61. Bell GI, Burant CF, Takeda J, et al. Structure and function of mammalian facilitative sugar transporters. J Biol Chem. 1993;268(26):19161-19164.
62. Kahn BB. Facilitative glucose transporters: regulatory mechanisms and dysregulation in diabetes. J Clin Invest. 1992;89(5):1367-1374.
63. Thorens B, Weir GC, Leahy JL, et al. Reduced expression of the liver/beta-cell glucose transporter isoform in glucose-insensitive pancreatic beta cells of diabetic rats. Proc Natl Acad Sci U S A. 1990;87(17):6492-6496.
64. Cushman SW, Wardzala LJ. Potential mechanism of insulin action on glucose transport in the isolated rat adipose cell. Apparent translocation of intracellular transport systems to the plasma membrane. J Biol Chem. 1980;255(10):4758-4762.
65. Katz EB, Stenbit AE, Hatton K, et al. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature. 1995;377(6545):151-155.
66. Guillam MT, Hummler E, Schaerer E, et al. Early diabetes and abnormal postnatal pancreatic islet development in mice lacking Glut-2. Nat Genet. 1997;17(3):327-330.
67. Ciaraldi TP, Horuk R, Matthaei S. Biochemical and functional characterization of the rat liver glucose-transport system. Comparisons with the adipocyte glucose-transport system. Biochem J. 1986;240(1):115-123.
68. Oka Y, Asano T, Shibasaki Y, et al. Increased liver glucose-transporter protein and mRNA in streptozocin-induced diabetic rats. Diabetes. 1990;39(4):441-446.
69. Andersen DK, Wong HC, Ruiz CL, et al. Pancreatic polypeptide (PP) immunodeficiency reproduces the altered hepatic glucose responses of chronic pancreatitis (CP). Pancreas. 1994;64:781.
70. Nathan JD, Zdankiewicz PD, Wang J, et al. Impaired hepatocyte glucose transport protein (GLUT2) internalization in chronic pancreatitis. Pancreas. 2001;22(2):172-178.
71. Slezak LA, Quinn AS, Sritharan KC, et al. Binding forces of hepatic microsomal and plasma membrane proteins in normal and pancreatitic rats: an AFM force spectroscopic study. Microsc Res Tech. 1999;44:363-367.
72. Sritharan KC, Aspelund G, Slezak LA, et al. Impaired recruitment of hepatocyte vesicle associated membrane protein (VAMP) by feeding in chronic pancreatitis. Gastroenterol. 2000;118(2):A429.
73. Elahi D, McAloon-Dyke M, Fukagawa N, et al. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept. 1994;51:63-74.
74. Kieffer T, Habener J. The glucagon-like peptides. Endocr Rev. 1999;20:876-913.
75. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(7):3082-3089.
76. Xu G, Stoffers D, Habener J, et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270-2276.
77. Stoffers D, Kieffer T, Hussain M, et al. Insulinotropic glucagon-like peptide-1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes. 2000;49:741-748.
78. Aspelund G, Egan J, Slezak L, et al. Glucagon-like peptide-1 and exendin-4 improve glucose tolerance and induce islet cell growth during chronic pancreatitis in rats. Surg Forum. 2000;51:40-42.
79. Buchler MW, Friess H, Muller MW, et al. Randomized trial of duodenum-preserving pancreatic head resection versus pylorus-preserving Whipple in chronic pancreatitis. Am J Surg. 1995;169(1):65-69. [discussion 69-70].
80. Izbicki JR, Bloechle C, Broering DC, et al. Longitudinal V-shaped excision of the ventral pancreas for small duct disease in severe chronic pancreatitis: prospective evaluation of a new surgical procedure. Ann Surg. 1998;227(2):213-219.
81. Aspelund G, Topazian MD, Lee JH, et al. Improved outcomes for benign disease with limited pancreatic head resection. J Gastrointest Surg. 2005;9(3):400-409.
82. Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care. 2006;29(2):435-449.